NASDAQ:PODD - Insulet Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $283.50
  • Forecasted Upside: -5.09 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$298.69
▼ -1.24 (-0.41%)

This chart shows the closing price for PODD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Insulet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PODD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PODD

Analyst Price Target is $283.50
▼ -5.09% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $283.50, with a high forecast of $325.00 and a low forecast of $245.00. The average price target represents a -5.09% upside from the last price of $298.69.

This chart shows the closing price for PODD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 investment analysts is to buy stock in Insulet. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 1 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 1 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 9 hold ratings
  • 1 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 1 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/20/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/6/2021SVB LeerinkLower Price TargetOutperform$325.00 ➝ $300.00High
8/6/2021Canaccord GenuityBoost Price TargetBuy$280.00 ➝ $300.00High
8/6/2021CitigroupBoost Price TargetBuy$310.00 ➝ $325.00High
7/21/2021CowenBoost Price TargetOutperform$285.00 ➝ $310.00Low
7/20/2021SVB LeerinkBoost Price TargetOutperform$300.00 ➝ $325.00Low
5/24/2021BarclaysInitiated CoverageOverweight$300.00Low
5/7/2021Raymond JamesLower Price TargetOutperform$296.00 ➝ $285.00High
5/7/2021SVB LeerinkLower Price TargetOutperform$320.00 ➝ $300.00High
5/7/2021Piper SandlerLower Price TargetNeutral$260.00 ➝ $250.00High
5/7/2021BTIG ResearchReiterated RatingHoldHigh
4/1/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$275.00 ➝ $320.00Low
3/19/2021Canaccord GenuityUpgradeHold ➝ Buy$280.00High
3/2/2021SVB LeerinkBoost Price TargetMarket Perform$255.00 ➝ $275.00Low
2/25/2021OppenheimerBoost Price TargetMarket Perform$235.00 ➝ $277.00High
2/24/2021SVB LeerinkReiterated RatingMarket Perform$255.00 ➝ $275.00High
2/24/2021Raymond JamesBoost Price TargetOutperform$282.00 ➝ $296.00Low
2/1/2021BTIG ResearchReiterated RatingHoldLow
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$260.00Medium
1/15/2021Wells Fargo & CompanyReiterated RatingBuyMedium
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$255.00 ➝ $268.00Medium
12/15/2020Morgan StanleyBoost Price TargetEqual Weight$246.00 ➝ $276.00Low
11/5/2020Canaccord GenuityBoost Price TargetHold$210.00 ➝ $240.00High
11/5/2020UBS GroupBoost Price TargetNeutral$230.00 ➝ $245.00Medium
11/5/2020Wells Fargo & CompanyBoost Price TargetOverweight$250.00 ➝ $266.00High
11/5/2020Raymond JamesBoost Price TargetOutperform$249.00 ➝ $250.00High
11/5/2020Morgan StanleyBoost Price TargetEqual Weight$232.00 ➝ $246.00High
10/12/2020SVB LeerinkBoost Price TargetMarket Perform$240.00 ➝ $255.00Low
8/7/2020Morgan StanleyBoost Price TargetEqual Weight$222.00 ➝ $232.00High
8/7/2020OppenheimerReiterated RatingHold$235.00Medium
8/7/2020StephensBoost Price TargetPositive ➝ Equal Weight$165.00 ➝ $230.00Medium
8/7/2020SVB LeerinkBoost Price TargetMarket Perform$215.00 ➝ $240.00Medium
8/7/2020Raymond JamesBoost Price TargetOutperform$200.00 ➝ $249.00Medium
8/7/2020CitigroupBoost Price TargetBuy$200.00 ➝ $255.00Medium
8/6/2020Piper SandlerReiterated RatingOverweight$235.00 ➝ $260.00Medium
7/28/2020Wells Fargo & CompanyInitiated CoverageOverweight$231.00High
7/7/2020CowenBoost Price TargetPositive ➝ Outperform$220.00 ➝ $230.00Low
6/9/2020Raymond JamesLower Price TargetOutperform$220.00 ➝ $200.00Low
5/8/2020CfraBoost Price TargetSell$162.00 ➝ $179.00Low
5/8/2020UBS GroupBoost Price TargetNeutral$195.00 ➝ $213.00High
5/8/2020Stifel NicolausBoost Price TargetHold$161.00 ➝ $195.00High
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$200.00 ➝ $235.00High
5/8/2020Robert W. BairdBoost Price Target$189.00 ➝ $242.00High
5/8/2020Morgan StanleyBoost Price TargetEqual Weight$186.00 ➝ $222.00Medium
5/8/2020SVB LeerinkBoost Price TargetMarket Perform$200.00 ➝ $230.00High
5/8/2020CitigroupBoost Price TargetBuy$206.00 ➝ $250.00High
4/27/2020Raymond JamesBoost Price TargetOutperform$205.00 ➝ $220.00Medium
4/24/2020SVB LeerinkDowngradeOutperform ➝ Market PerformLow
4/3/2020Bank of AmericaInitiated CoverageNeutral$200.00Medium
3/31/2020Berenberg BankDowngradeBuy ➝ HoldHigh
3/27/2020Morgan StanleyBoost Price TargetEqual Weight$181.00 ➝ $186.00Low
3/27/2020CitigroupLower Price TargetBuy$220.00 ➝ $206.00Medium
3/4/2020CitigroupInitiated CoverageBuy$220.00Low
2/26/2020Piper SandlerReiterated RatingBuy$200.00High
2/26/2020CowenReiterated RatingBuyHigh
2/26/2020CfraLower Price TargetSell$163.00 ➝ $162.00Low
2/26/2020Robert W. BairdLower Price TargetOutperform$225.00 ➝ $215.00High
2/26/2020BTIG ResearchReiterated RatingHoldHigh
2/26/2020Raymond JamesLower Price TargetOutperform$213.00 ➝ $205.00High
2/6/2020Raymond JamesBoost Price TargetOutperform$158.00 ➝ $213.00Medium
12/20/2019JPMorgan Chase & Co.Boost Price TargetOverweight$170.00 ➝ $200.00Medium
12/17/2019Morgan StanleyBoost Price TargetEqual Weight$148.00 ➝ $181.00Low
12/10/2019CfraInitiated CoverageSell$163.00Medium
12/9/2019Canaccord GenuityBoost Price TargetHold$150.00 ➝ $165.00Low
11/18/2019Piper Jaffray CompaniesBoost Price TargetOverweight$170.00 ➝ $200.00Low
11/6/2019Raymond JamesBoost Price TargetOutperform$135.00 ➝ $158.00High
11/6/2019Piper Jaffray CompaniesReiterated RatingOverweight$160.00 ➝ $170.00High
10/22/2019Stifel NicolausInitiated CoverageHold$163.00High
10/21/2019CowenSet Price TargetBuy$165.00Medium
10/18/2019Canaccord GenuityDowngradeBuy ➝ Hold$135.00 ➝ $145.00Medium
10/14/2019BTIG ResearchDowngradeBuy ➝ NeutralMedium
10/4/2019UBS GroupDowngradeBuy ➝ Neutral$155.00 ➝ $160.00Low
10/3/2019GuggenheimDowngradeBuy ➝ NeutralMedium
9/24/2019SVB LeerinkBoost Price TargetOutperform$160.00 ➝ $185.00High
9/23/2019Piper Jaffray CompaniesReiterated RatingBuyLow
8/6/2019Morgan StanleyBoost Price TargetEqual Weight$127.00 ➝ $135.00High
8/6/2019BTIG ResearchBoost Price TargetBuy$140.00High
8/6/2019BMO Capital MarketsBoost Price TargetOutperform$130.00 ➝ $150.00High
8/6/2019Jefferies Financial GroupBoost Price TargetBuy$105.00 ➝ $140.00High
8/6/2019Raymond JamesBoost Price TargetOutperform$125.00 ➝ $135.00High
8/6/2019GuggenheimBoost Price TargetBuy ➝ Positive$100.00 ➝ $145.00High
8/6/2019Canaccord GenuityBoost Price TargetBuy$110.00 ➝ $135.00High
8/6/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$120.00 ➝ $155.00High
8/6/2019Piper Jaffray CompaniesBoost Price TargetOverweight$130.00 ➝ $160.00High
7/16/2019Morgan StanleyBoost Price TargetEqual Weight$98.00 ➝ $127.00Low
7/10/2019SVB LeerinkReiterated RatingOutperformLow
6/28/2019Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Positive$110.00 ➝ $130.00High
6/27/2019JPMorgan Chase & Co.Boost Price TargetNeutral$90.00 ➝ $120.00Low
6/13/2019UBS GroupBoost Price TargetBuy$110.00 ➝ $130.00Low
6/10/2019Northland SecuritiesDowngradeOutperform ➝ Market Perform$100.00Low
5/6/2019Canaccord GenuityReiterated RatingBuy$100.00 ➝ $110.00High
5/6/2019BTIG ResearchUpgradeNeutral ➝ Buy$115.00High
2/26/2019OppenheimerSet Price TargetHold$100.00Medium
2/26/2019Northland SecuritiesReiterated RatingBuy$100.00High
2/19/2019Canaccord GenuityBoost Price TargetBuy$90.00 ➝ $100.00Medium
1/3/2019SVB LeerinkReiterated RatingOutperform$110.00 ➝ $100.00Medium
1/2/2019Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$105.00 ➝ $90.00High
11/27/2018UBS GroupInitiated CoverageBuy$105.00Medium
11/2/2018OppenheimerSet Price TargetHold$100.00High
10/11/2018Morgan StanleyBoost Price TargetEqual Weight$96.00 ➝ $105.00Medium
9/11/2018SVB LeerinkReiterated RatingOutperform$130.00Medium
8/3/2018Jefferies Financial GroupReiterated RatingBuy$97.00Low
8/3/2018OppenheimerSet Price TargetHold$96.00High
7/10/2018BMO Capital MarketsBoost Price TargetTop Pick$115.00Medium
6/4/2018Piper Jaffray CompaniesBoost Price TargetOverweight$106.00Low
6/1/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$87.00 ➝ $96.00Low
5/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$96.00 ➝ $100.00Low
5/4/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$90.00 ➝ $100.00High
5/4/2018Northland SecuritiesReiterated RatingBuy$100.00Low
5/4/2018OppenheimerSet Price TargetHold$90.00High
5/3/2018Piper Jaffray CompaniesBoost Price TargetOverweight$88.00 ➝ $90.00High
5/2/2018Canaccord GenuityReiterated RatingBuy$90.00Medium
4/20/2018Berenberg BankInitiated CoverageBuy$100.00Medium
4/3/2018GuggenheimInitiated CoverageBuy$105.00Low
3/5/2018BMO Capital MarketsInitiated CoverageOutperform$90.00High
2/23/2018Jefferies Financial GroupReiterated RatingBuy$90.00Low
2/23/2018Canaccord GenuityBoost Price TargetNeutral$78.00 ➝ $88.00Low
2/22/2018CowenReiterated RatingOutperform ➝ Outperform$80.00 ➝ $90.00Medium
2/22/2018OppenheimerSet Price TargetHold$82.00High
2/22/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$76.00 ➝ $87.00High
2/22/2018StephensReiterated RatingEqual Weight ➝ Equal Weight$60.00 ➝ $81.00High
2/22/2018BarclaysReiterated RatingOverweight ➝ Overweight$85.00 ➝ $90.00High
1/8/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$80.00High
1/8/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
12/13/2017BarclaysReiterated RatingBuy$78.00Low
11/20/2017BarclaysBoost Price TargetOverweight$70.00 ➝ $75.00N/A
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$55.00 ➝ $63.00N/A
11/3/2017Jefferies Financial GroupBoost Price TargetBuy$58.00 ➝ $67.00N/A
11/3/2017Robert W. BairdBoost Price TargetOutperform$65.00 ➝ $72.00N/A
11/1/2017Canaccord GenuityUpgradeHold ➝ Buy$50.00 ➝ $65.00N/A
10/13/2017Robert W. BairdSet Price TargetBuy$65.00N/A
10/12/2017SVB LeerinkReiterated RatingOutperform$65.00 ➝ $74.00N/A
10/10/2017WedbushReiterated RatingBuy$60.00 ➝ $65.00N/A
9/27/2017Canaccord GenuityReiterated RatingHold$50.00Medium
9/15/2017BarclaysInitiated CoverageOverweight ➝ Overweight$65.00Low
8/9/2017Jefferies Financial GroupReiterated RatingBuy$48.00 ➝ $58.00Low
8/4/2017OppenheimerSet Price TargetHold$55.00Low
8/4/2017Northland SecuritiesReiterated RatingBuyLow
8/4/2017CowenReiterated RatingOutperform$52.00 ➝ $63.00High
7/22/2017OppenheimerReiterated RatingHoldHigh
7/17/2017BTIG ResearchDowngradeBuy ➝ NeutralMedium
7/14/2017CowenReiterated RatingBuy$52.00Medium
7/14/2017Jefferies Financial GroupReiterated RatingBuy$48.00Low
7/11/2017Canaccord GenuityReiterated RatingHold$42.00 ➝ $50.00Low
6/16/2017Jefferies Financial GroupReiterated RatingBuyLow
5/26/2017Canaccord GenuityReiterated RatingHold$42.00Low
5/25/2017William BlairReiterated RatingOutperform ➝ OutperformLow
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$47.00Low
5/14/2017B. RileyReiterated RatingNeutral$44.00Low
5/10/2017Jefferies Financial GroupLower Price TargetBuy$53.00 ➝ $48.00Medium
5/10/2017BTIG ResearchUpgradeNeutral ➝ Buy$47.00Medium
5/9/2017B. RileyReiterated RatingNeutral$44.00High
5/9/2017OppenheimerSet Price TargetHold$46.00High
5/9/2017Northland SecuritiesReiterated RatingBuy$50.00High
4/13/2017Jefferies Financial GroupReiterated RatingBuy$53.00Low
3/6/2017B. RileyReiterated RatingNeutral$44.00N/A
3/6/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
3/1/2017B. RileyReiterated RatingNeutral$44.00N/A
2/28/2017OppenheimerSet Price TargetHold$46.00N/A
2/28/2017Jefferies Financial GroupBoost Price TargetBuy$45.00 ➝ $53.00N/A
2/28/2017WedbushBoost Price TargetOutperform ➝ Outperform$48.00 ➝ $50.00N/A
2/27/2017Feltl & Co.DowngradeBuy ➝ HoldN/A
2/13/2017Canaccord GenuityReiterated RatingHold$39.00N/A
1/23/2017Canaccord GenuitySet Price TargetHold$39.00N/A
1/8/2017BTIG ResearchReiterated RatingBuy$42.00N/A
1/6/2017Robert W. BairdUpgradeNeutral ➝ Outperform$39.00 ➝ $47.00N/A
11/17/2016JPMorgan Chase & Co.Reiterated RatingHold$38.00N/A
11/17/2016WedbushReiterated RatingOutperform$48.00N/A
11/9/2016B. RileyReiterated RatingNeutral$40.00N/A
11/7/2016SVB LeerinkReiterated RatingOutperform$55.00 ➝ $50.00N/A
11/6/2016Canaccord GenuitySet Price TargetHold$39.00N/A
11/4/2016B. RileyReiterated RatingNeutral$40.00N/A
11/4/2016JPMorgan Chase & Co.Reiterated RatingHold$38.00N/A
11/4/2016BTIG ResearchUpgradeNeutral ➝ Buy$42.00N/A
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 5 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 10 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/20/2021

Current Sentiment

  • 10 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Insulet logo
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Read More

Today's Range

Now: $298.69
Low: $298.51
High: $304.04

50 Day Range

MA: $293.01
Low: $275.03
High: $307.27

52 Week Range

Now: $298.69
Low: $214.93
High: $309.99

Volume

204,272 shs

Average Volume

439,492 shs

Market Capitalization

$20.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Insulet?

The following Wall Street sell-side analysts have issued reports on Insulet in the last year: Barclays PLC, BTIG Research, Canaccord Genuity, Citigroup Inc., Cowen Inc, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Smith Barney Citigroup, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for PODD.

What is the current price target for Insulet?

12 Wall Street analysts have set twelve-month price targets for Insulet in the last year. Their average twelve-month price target is $283.50, suggesting a possible downside of 5.7%. Citigroup Inc. has the highest price target set, predicting PODD will reach $325.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $245.00 for Insulet in the next year.
View the latest price targets for PODD.

What is the current consensus analyst rating for Insulet?

Insulet currently has 6 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PODD will outperform the market and that investors should add to their positions of Insulet.
View the latest ratings for PODD.

What other companies compete with Insulet?

How do I contact Insulet's investor relations team?

Insulet's physical mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier's listed phone number is (978) 600-7000 and its investor relations email address is [email protected] The official website for Insulet is www.insulet.com.